2019 Daejeon University Seoul Oriental Hospital International Symposium, co-organized by Daejeon University Seoul Oriental Hospital East-West Cancer Center and Daejeon University Dunsan Oriental Hospital Clinical Trial Center, was held at the 4th floor of Daejeon University Seoul Oriental Hospital in HYEHWA HALL.

The conference, entitled “New Era of Cancer Treatment, Integrative Oncology in the World,” was held in Beijing. Prominent speakers from home and abroad participated, including Professor Kang and Professor Chun Hao of Shanghai Fudan University Oncology Hospital as a special guest speaker, confirming the latest clinical research on oriental medicine cancer treatment and the superiority of modern standard treatment and integrated cancer treatment.
 

The conference included a variety of recent trends and research papers, including the latest integrated cancer management using traditional Korean medicine, the diagnosis and standard treatment of lung cancer, lung cancer immunotherapy and integrated cancer treatment, lung cancer target cancer treatment and integrated cancer treatment.

The president of Daejeon University Seoul Oriental Medicine Hospital said in a welcome speech: “Integrated oncology research serves as a guide to help complementary alternative medicine doctors become accustomed to medical research, judges whether their treatment is going in the right direction, and It will help to provide the foundation. ”

Prof. Hong Kang Kang of Gwanganmun Hospital presented a typical cohort study on the integrated management of Chinese medicine in the treatment of patients with non-small cell lung cancer. The results showed that the median overall survival of lung cancer patients was higher than that of patients receiving bilateral monotherapy alone, while the median progression-free survival was also combined. Was higher than the bilateral monotherapy group. In addition, patients who received integrative treatment showed improved physical activity index and quality of life, and decreased side effects of digestive system after chemo and radiation therapy. In addition, Professor Chun Hao of Shanghai Fudan University presented an extended clinical study of patients who took herbal medicine after pancreatic cancer surgery.

At the conference, Korean speakers also presented the latest integrated cancer management, diagnosis and standard treatment of lung cancer, lung cancer immunotherapy and integrative treatment, lung cancer target cancer treatment and integrated cancer treatment using traditional Korean medicine. In particular, Professor Jeon, Hyung-jun of Daejeon University Seoul Oriental Hospital received attention for his research on the treatment of lung cancer with afatinib and Samchiongchocho. Samchilchungchojeong is currently the first clinical trial approved by Korea Food and Drug Administration. It is a phase 2 multi-center clinical trial that evaluates disease response rate, progression-free survival, quality of life, and immune index by using anticancer drugs for lung cancer. Now in progress.

The research team of Daejeon University Dunsan Oriental Hospital, currently selected for the Korean medicine-based convergence technology development project of the Ministry of Health and Welfare, is conducting a large-scale multi-center clinical research on oriental medicine treatment of lung cancer with a total funding of 3.5 billion won over the next three years and six months. . In the clinical trial, Catholic University Seoul St. Mary's Hospital, Konyang University Hospital, Kosin University Gospel Hospital, Yangsan Pusan ​​National University Hospital, Kangdong Kyunghee University Oriental Hospital, and Pusan ​​National University Oriental Hospital jointly participate.